13 completed, 3 terminated, 1 unknown, 1 withdrawn. 18 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 13, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 5, Terminated 2 |
Follow CureVac: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg - Squamous NSCLC | Phase 1 | Withdrawn | CureVac | 2025-07-30 | 2026-05-29 | |
| Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg - Glioblastoma | Phase 1 | Completed | CureVac | 37 | 2023-06-01 | 2026-02-18 |
| A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z - Influenza, Human | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1275 | 2023-04-27 | 2025-07-23 |
| A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults GSK4382276A Dose level 1, GSK4382276A Dose level 2, GSK4382276A Dose level 3 - Influenza, Human | Phase 1 | Completed | GlaxoSmithKline | 324 | 2022-08-09 | 2026-03-10 |
| Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg) - COVID-19, SARS-CoV-2 | Phase 1 | Completed | GlaxoSmithKline | 99 | 2022-03-24 | 2024-08-12 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults CVSQIV - Influenza | Phase 1 | Completed | CureVac | 240 | 2022-02-07 | 2023-06-06 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV Vaccine, Placebo - Severe Acute Respiratory Syndrome, Coronavirus | Phase 1 | Completed | CureVac | 280 | 2020-06-18 | 2023-01-30 |
| A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults Rabipur®, Rabies mRNA vaccine CV7202 - Rabies | Phase 1 | Completed | CureVac | 53 | 2018-10-12 | 2024-12-19 |
| Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Durvalumab, Tremelimumab, BI 1361849 - Metastatic Non-small Cell Lung Cancer, NSCLC | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 61 | 2017-12-20 | 2022-10-10 |
| Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC CV8102, CV8102 + anti-PD-1 therapy - Melanoma (Skin), Squamous Cell Carcinoma of the Skin | Phase 1 | Unknown | CureVac | 98 | 2017-09-25 | 2021-11-04 |
| IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients IMA970A plus CV8102 and Cyclophosphamide - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute, Naples | 22 | 2017-09-18 | 2020-02-05 |
| Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults CV8102, Rabipur, CV8102 + Rabipur - Rabies | Phase 1 | Completed | CureVac | 72 | 2014-09-01 | 2018-06-06 |
| RNActive® Rabies Vaccine (CV7201) in Healthy Adults CV7201 mRNA - Rabies | Phase 1 | Completed | CureVac | 101 | 2013-10-01 | 2018-10-29 |
| Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC) CV9202, local radiation - Non-Small Cell Lung Carcinoma | Phase 1 | Terminated | CureVac | 26 | 2013-04-01 | 2016-08-05 |
| Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer CV9104, Placebo - Prostate Cancer | Phase 1 / Phase 2 | Terminated | CureVac | 197 | 2012-08-01 | 2017-02-17 |
| Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) CV9201 - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | CureVac | 46 | 2009-05-01 | 2018-03-20 |
| RNActive®-Derived Therapeutic Vaccine CV9103 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Terminated | University of Florida | 6 | 2009-05-01 | 2012-04-04 |
| Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease CV9103 - Hormonal Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | CureVac | 48 | 2009-01-01 | 2018-03-20 |
Carcinoma, Non-Small-Cell Lung (3) · Influenza, Human (3) · Rabies (3) · COVID-19 (2) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Hepatocellular (1) · Coronavirus Infections (1) · Glioblastoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Severe Acute Respiratory Syndrome (1) · Squamous Cell Carcinoma of Head and Neck (1)
CVnCoV COVID-19 vaccine (1) · Cyclophosphamide (1) · durvalumab (1) · tremelimumab (1)
Germany (11) · Belgium (6) · Spain (5) · United States (5) · France (3) · Switzerland (3) · Austria (2) · Canada (2) · Italy (2) · United Kingdom (2) · Czechia (1) · Netherlands (1) · Panama (1) · Poland (1) · Russia (1)
Alexander Knuth, Prof. Dr. (1) · Alfred Zippelius, Prof. Dr. (1) · Arnulf Stenzl, Prof. Dr. (1) · Franz-Josef Falkner von Sonnenburg, MD (1) · Ingo Meyer, MD (1) · Jhanelle Gray, MD (1) · Johannes Vieweg, MD FACS (1) · Kurt Miller, Professor (1) · Thomas Eigentler, Prof. Dr. (1)
PMID 21150709, PMID 25288198, PMID 28754494, PMID 30736848, PMID 33487468, PMID 35421231, PMID 36319717, PMID 39904560, PMID 41051649, PMID 41701031, PMID 42875683
2017 (1)